Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.55 |
| ▸ | NSD2 | O96028 | 1/20 | 0.55 |
| ▸ | EGFR | P00533 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18984785 | 0.75 | MAPT (0.88) | MAPTALDH1A1L3MBTL1MAPK1TDP1 | |
| SCHEMBL18984695 | 0.74 | MAPT (0.85) | MAPTALDH1A1L3MBTL1MAPK1TDP1 | |
| SCHEMBL5535931 | 0.71 | ALDH1A1 (0.85) | MAPTALDH1A1L3MBTL1MAPK1TDP1 | |
| SCHEMBL2362908 | 0.71 | MAPT (0.85) | MAPTALDH1A1L3MBTL1MAPK1TDP1 | |
| SCHEMBL1566522 | 0.71 | MAPT (0.56) | MAPTALDH1A1L3MBTL1MAPK1TDP1 | |
| SCHEMBL187706 | 0.71 | L3MBTL1 (1.00) | MAPTALDH1A1L3MBTL1MAPK1TDP1 | |
| SCHEMBL2229694 | 0.69 | ADORA2A (0.50) | MAPTALDH1A1L3MBTL1MAPK1TDP1 | |
| SCHEMBL2961474 | 0.69 | MAOA (0.56) | MAPTALDH1A1L3MBTL1MAPK1TDP1 | |
| SCHEMBL873779 | 0.69 | ALDH1A1 (0.55) | MAPTALDH1A1L3MBTL1MAPK1TDP1 | |
| SCHEMBL4958613 | 0.69 | MAPT (0.55) | MAPTALDH1A1L3MBTL1MAPK1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9968602-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2018-05-15 | — | — | US | claimed |
| US-20140030317-A1 | MODULATION OF CELL FATES AND ACTIVITIES BY PHTHALAZINEDIONES | Occhiuti & Rohlicek LLP | 2014-01-30 | — | — | US | claimed |
| US-7326690-B2 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2008-02-05 | — | — | US | claimed |
| US-20070142303-A1 | Modulation of cell fates and activities by phthalazinediones | BACH PHARMA, INC. (US) | 2007-06-21 | — | — | US | claimed |
| US-12246068-B2 | Enzymatically activatable peptide-redox modulator conjugates and use thereof | BRANDEIS UNIVERSITY (US) | 2025-03-11 | — | — | US | disclosed |
| WO-2018129171-A1 | ENZYMATICALLY ACTIVATABLE PEPTIDE-REDOX MODULATOR CONJUGATES AND USE THEREOF | BRANDEIS UNIVERSITY (US) | 2018-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12246068-B2 | Enzymatically activatable peptide-redox modulator conjugates and use thereof | GPX1, GPX4, ENPEP | MAPT 4553/4885ALDH1A1 777/4885L3MBTL1 1562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.